191 related articles for article (PubMed ID: 25449809)
1. Encapsulation of beraprost sodium in nanoparticles: analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension.
Ishihara T; Hayashi E; Yamamoto S; Kobayashi C; Tamura Y; Sawazaki R; Tamura F; Tahara K; Kasahara T; Ishihara T; Takenaga M; Fukuda K; Mizushima T
J Control Release; 2015 Jan; 197():97-104. PubMed ID: 25449809
[TBL] [Abstract][Full Text] [Related]
2. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-Mediated Targeting of Pitavastatin to Small Pulmonary Arteries and Leukocytes by Intravenous Administration Attenuates the Progression of Monocrotaline-Induced Established Pulmonary Arterial Hypertension in Rats.
Ichimura K; Matoba T; Koga JI; Nakano K; Funamoto D; Tsutsui H; Egashira K
Int Heart J; 2018 Nov; 59(6):1432-1444. PubMed ID: 30369578
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Tawara S; Fukumoto Y; Shimokawa H
J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension.
Chen L; Nakano K; Kimura S; Matoba T; Iwata E; Miyagawa M; Tsujimoto H; Nagaoka K; Kishimoto J; Sunagawa K; Egashira K
Hypertension; 2011 Feb; 57(2):343-50. PubMed ID: 21220711
[TBL] [Abstract][Full Text] [Related]
6. Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Gupta N; Ibrahim HM; Ahsan F
J Pharm Sci; 2014 Nov; 103(11):3743-3753. PubMed ID: 25266507
[TBL] [Abstract][Full Text] [Related]
7. Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model.
Liu K; Zhang X; Cao G; Liu Y; Liu C; Sun H; Pang X
Int J Nanomedicine; 2016; 11():2587-99. PubMed ID: 27354791
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of prostaglandin E(1) phosphate derivatives and their encapsulation in biodegradable nanoparticles.
Takeda M; Maeda T; Ishihara T; Sakamoto H; Yuki K; Takasaki N; Nishimura F; Yamashita T; Tanaka K; Takenaga M; Igarashi R; Higaki M; Yamakawa N; Okamoto Y; Ogawa H; Otsuka M; Mizushima Y; Mizushima T
Pharm Res; 2009 Jul; 26(7):1792-800. PubMed ID: 19415470
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension.
Kimura S; Egashira K; Chen L; Nakano K; Iwata E; Miyagawa M; Tsujimoto H; Hara K; Morishita R; Sueishi K; Tominaga R; Sunagawa K
Hypertension; 2009 May; 53(5):877-83. PubMed ID: 19307469
[TBL] [Abstract][Full Text] [Related]
10. [Combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats].
Ueno M; Miyauchi T; Sakai S; Yamauchi-Kohno R; Goto K; Yamaguchi I
J Cardiol; 2003 Jan; 41(1):45-6. PubMed ID: 12564116
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension.
Segura-Ibarra V; Amione-Guerra J; Cruz-Solbes AS; Cara FE; Iruegas-Nunez DA; Wu S; Youker KA; Bhimaraj A; Torre-Amione G; Ferrari M; Karmouty-Quintana H; Guha A; Blanco E
Int J Pharm; 2017 May; 524(1-2):257-267. PubMed ID: 28359821
[TBL] [Abstract][Full Text] [Related]
12. Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats.
Yuki H; Sato S; Arisaka Y; Kato S; Tomoike H
Tohoku J Exp Med; 1994 Aug; 173(4):371-5. PubMed ID: 7825169
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
14. Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug.
Surwase SS; Munot NM; Idage BB; Idage SB
Drug Deliv Transl Res; 2017 Jun; 7(3):416-427. PubMed ID: 28324320
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
16. Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats.
Ueno M; Miyauchi T; Sakai S; Goto K; Yamaguchi I
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S305-10. PubMed ID: 11078405
[TBL] [Abstract][Full Text] [Related]
17. Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly(ethylene glycol)-poly(D,L-lactide) nanoparticle with longer survival time.
Xu W; Ling P; Zhang T
Int J Pharm; 2014 Jan; 460(1-2):173-80. PubMed ID: 24172796
[TBL] [Abstract][Full Text] [Related]
18. [Protective effects of beraprost plus simvastatin on monocrotaline-induced pulmonary arterial hypertension in rats].
Wang SH; Liu S; Yang JH; Wang ZZ; Li J; Hou WW
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(22):1691-5. PubMed ID: 24124673
[TBL] [Abstract][Full Text] [Related]
19. Tissue localization of nanoparticles is altered due to hypoxia resulting in poor efficacy of curcumin nanoparticles in pulmonary hypertension.
Devadasu VR; Wadsworth RM; Ravi Kumar MN
Eur J Pharm Biopharm; 2012 Apr; 80(3):578-84. PubMed ID: 22227367
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis.
Sakai T; Ishihara T; Higaki M; Akiyama G; Tsuneoka H
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1516-21. PubMed ID: 21178146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
